View Future Growthatect 과거 순이익 실적과거 기준 점검 4/6atect의 수입은 연평균 -25%의 비율로 감소해 온 반면, Life Sciences 산업은 수입이 연평균 8.6% 감소했습니다. 매출은 연평균 1.9%의 비율로 증가해 왔습니다. atect의 자기자본이익률은 7.7%이고 순이익률은 4.2%입니다.핵심 정보-24.98%순이익 성장률-25.02%주당순이익(EPS) 성장률Life Sciences 산업 성장률32.01%매출 성장률1.93%자기자본이익률7.72%순이익률4.20%다음 순이익 업데이트07 Aug 2026최근 과거 실적 업데이트공고 • Jun 28atect corporation to Report Q1, 2027 Results on Aug 07, 2026atect corporation announced that they will report Q1, 2027 results on Aug 07, 2026Reported Earnings • May 17Full year 2026 earnings released: EPS: JP¥31.89 (vs JP¥9.05 in FY 2025)Full year 2026 results: EPS: JP¥31.89 (up from JP¥9.05 in FY 2025). Revenue: JP¥3.36b (up 4.9% from FY 2025). Net income: JP¥141.0m (up 253% from FY 2025). Profit margin: 4.2% (up from 1.2% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥8.14 (vs JP¥0.45 in 3Q 2025)Third quarter 2026 results: EPS: JP¥8.14 (up from JP¥0.45 in 3Q 2025). Revenue: JP¥876.0m (up 13% from 3Q 2025). Net income: JP¥36.0m (up JP¥34.0m from 3Q 2025). Profit margin: 4.1% (up from 0.3% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.공고 • Dec 03atect corporation to Report Q3, 2026 Results on Feb 13, 2026atect corporation announced that they will report Q3, 2026 results on Feb 13, 2026공고 • Nov 05atect corporation to Report Q2, 2026 Results on Nov 14, 2025atect corporation announced that they will report Q2, 2026 results on Nov 14, 2025Reported Earnings • Aug 10First quarter 2026 earnings released: EPS: JP¥13.12 (vs JP¥9.05 in 1Q 2025)First quarter 2026 results: EPS: JP¥13.12 (up from JP¥9.05 in 1Q 2025). Revenue: JP¥826.0m (down 7.0% from 1Q 2025). Net income: JP¥58.0m (up 45% from 1Q 2025). Profit margin: 7.0% (up from 4.5% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.모든 업데이트 보기Recent updates공고 • Jun 28atect corporation to Report Q1, 2027 Results on Aug 07, 2026atect corporation announced that they will report Q1, 2027 results on Aug 07, 2026Reported Earnings • May 17Full year 2026 earnings released: EPS: JP¥31.89 (vs JP¥9.05 in FY 2025)Full year 2026 results: EPS: JP¥31.89 (up from JP¥9.05 in FY 2025). Revenue: JP¥3.36b (up 4.9% from FY 2025). Net income: JP¥141.0m (up 253% from FY 2025). Profit margin: 4.2% (up from 1.2% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.공고 • May 13atect corporation, Annual General Meeting, Jun 24, 2026atect corporation, Annual General Meeting, Jun 24, 2026.Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥890, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 23x in the Life Sciences industry in Japan. Total returns to shareholders of 81% over the past three years.Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥817, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total returns to shareholders of 47% over the past three years.Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 26 June 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (2.8%).Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to JP¥741, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 25x in the Life Sciences industry in Japan. Total returns to shareholders of 38% over the past three years.Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥8.14 (vs JP¥0.45 in 3Q 2025)Third quarter 2026 results: EPS: JP¥8.14 (up from JP¥0.45 in 3Q 2025). Revenue: JP¥876.0m (up 13% from 3Q 2025). Net income: JP¥36.0m (up JP¥34.0m from 3Q 2025). Profit margin: 4.1% (up from 0.3% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 20%After last week's 20% share price gain to JP¥749, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 24x in the Life Sciences industry in Japan. Total returns to shareholders of 52% over the past three years.New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.1% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥3.00b market cap, or US$19.7m).Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥684, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 24x in the Life Sciences industry in Japan. Total returns to shareholders of 34% over the past three years.분석 기사 • Jan 20atect corporation's (TSE:4241) Prospects Need A Boost To Lift SharesWith a price-to-sales (or "P/S") ratio of 0.8x atect corporation ( TSE:4241 ) may be sending bullish signals at the...공고 • Dec 03atect corporation to Report Q3, 2026 Results on Feb 13, 2026atect corporation announced that they will report Q3, 2026 results on Feb 13, 2026Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥510, the stock trades at a trailing P/E ratio of 38.9x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total returns to shareholders of 6.1% over the past three years.분석 기사 • Nov 27atect (TSE:4241) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Nov 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 33% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (JP¥2.25b market cap, or US$14.4m).공고 • Nov 05atect corporation to Report Q2, 2026 Results on Nov 14, 2025atect corporation announced that they will report Q2, 2026 results on Nov 14, 2025Reported Earnings • Aug 10First quarter 2026 earnings released: EPS: JP¥13.12 (vs JP¥9.05 in 1Q 2025)First quarter 2026 results: EPS: JP¥13.12 (up from JP¥9.05 in 1Q 2025). Revenue: JP¥826.0m (down 7.0% from 1Q 2025). Net income: JP¥58.0m (up 45% from 1Q 2025). Profit margin: 7.0% (up from 4.5% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.New Risk • Aug 10New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 33% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (JP¥1.86b market cap, or US$12.6m).공고 • Aug 02atect corporation to Report Q1, 2026 Results on Aug 08, 2025atect corporation announced that they will report Q1, 2026 results on Aug 08, 2025Reported Earnings • May 21Full year 2025 earnings released: EPS: JP¥9.05 (vs JP¥55.19 loss in FY 2024)Full year 2025 results: EPS: JP¥9.05 (up from JP¥55.19 loss in FY 2024). Revenue: JP¥3.20b (flat on FY 2024). Net income: JP¥40.0m (up JP¥284.0m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.공고 • May 15atect corporation, Annual General Meeting, Jun 25, 2025atect corporation, Annual General Meeting, Jun 25, 2025.공고 • Mar 27atect corporation to Report Fiscal Year 2025 Results on May 14, 2025atect corporation announced that they will report fiscal year 2025 results on May 14, 2025Upcoming Dividend • Mar 21Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 27 June 2025. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 2.2%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (2.8%).New Risk • Feb 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥2.26b market cap, or US$15.1m).Reported Earnings • Feb 08Third quarter 2025 earnings released: EPS: JP¥0.45 (vs JP¥3.85 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥0.45 (up from JP¥3.85 loss in 3Q 2024). Revenue: JP¥773.0m (up 2.9% from 3Q 2024). Net income: JP¥2.00m (up JP¥19.0m from 3Q 2024). Profit margin: 0.3% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.분석 기사 • Jan 30Revenues Working Against atect corporation's (TSE:4241) Share Priceatect corporation's ( TSE:4241 ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy right now...공고 • Jan 17atect corporation to Report Q3, 2025 Results on Feb 07, 2025atect corporation announced that they will report Q3, 2025 results on Feb 07, 2025New Risk • Jan 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.1% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥1.88b market cap, or US$11.9m).New Risk • Dec 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.57b (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.1% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 26% per year over the past 5 years. Market cap is less than US$10m (JP¥1.57b market cap, or US$9.99m).Reported Earnings • Nov 11Second quarter 2025 earnings released: JP¥3.62 loss per share (vs JP¥6.33 profit in 2Q 2024)Second quarter 2025 results: JP¥3.62 loss per share (down from JP¥6.33 profit in 2Q 2024). Revenue: JP¥764.0m (down 8.5% from 2Q 2024). Net loss: JP¥16.0m (down 157% from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.Buy Or Sell Opportunity • Nov 11Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to JP¥464. The fair value is estimated to be JP¥614, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.공고 • Oct 11atect corporation to Report Q2, 2025 Results on Nov 08, 2024atect corporation announced that they will report Q2, 2025 results on Nov 08, 2024New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥2.26b market cap, or US$16.1m).분석 기사 • Aug 06atect corporation (TSE:4241) Looks Inexpensive After Falling 33% But Perhaps Not Attractive EnoughThe atect corporation ( TSE:4241 ) share price has fared very poorly over the last month, falling by a substantial 33...분석 기사 • Aug 04atect (TSE:4241) Has A Somewhat Strained Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...공고 • Jul 17atect corporation to Report Q1, 2025 Results on Aug 07, 2024atect corporation announced that they will report Q1, 2025 results on Aug 07, 2024New Risk • May 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 19% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (JP¥3.19b market cap, or US$20.5m).Reported Earnings • May 13Full year 2024 earnings released: JP¥55.19 loss per share (vs JP¥35.74 profit in FY 2023)Full year 2024 results: JP¥55.19 loss per share (down from JP¥35.74 profit in FY 2023). Revenue: JP¥3.18b (up 7.2% from FY 2023). Net loss: JP¥244.0m (down 254% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.공고 • May 12atect corporation, Annual General Meeting, Jun 26, 2024atect corporation, Annual General Meeting, Jun 26, 2024.Buy Or Sell Opportunity • Apr 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to JP¥790. The fair value is estimated to be JP¥1,004, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.공고 • Mar 28atect corporation to Report Fiscal Year 2024 Results on May 10, 2024atect corporation announced that they will report fiscal year 2024 results on May 10, 2024Buy Or Sell Opportunity • Mar 26Now 21% undervaluedOver the last 90 days, the stock has risen 12% to JP¥789. The fair value is estimated to be JP¥1,005, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.Upcoming Dividend • Mar 21Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 24 June 2024. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (2.3%).Buy Or Sell Opportunity • Mar 11Now 22% undervaluedOver the last 90 days, the stock has risen 12% to JP¥792. The fair value is estimated to be JP¥1,017, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥870, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 14x in the Life Sciences industry in Japan. Total loss to shareholders of 3.8% over the past three years.Reported Earnings • Feb 09Third quarter 2024 earnings released: JP¥3.85 loss per share (vs JP¥7.69 profit in 3Q 2023)Third quarter 2024 results: JP¥3.85 loss per share (down from JP¥7.69 profit in 3Q 2023). Revenue: JP¥751.0m (down 2.5% from 3Q 2023). Net loss: JP¥17.0m (down 150% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥1,080, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total returns to shareholders of 15% over the past three years.공고 • Jan 11atect corporation to Report Q3, 2024 Results on Feb 07, 2024atect corporation announced that they will report Q3, 2024 results on Feb 07, 2024Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to JP¥782, the stock trades at a trailing P/E ratio of 21.1x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 7.8% over the past three years.Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improves as stock rises 22%After last week's 22% share price gain to JP¥801, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 20% over the past three years.Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: JP¥6.33 (vs JP¥9.95 in 2Q 2023)Second quarter 2024 results: EPS: JP¥6.33 (down from JP¥9.95 in 2Q 2023). Revenue: JP¥835.0m (up 21% from 2Q 2023). Net income: JP¥28.0m (down 36% from 2Q 2023). Profit margin: 3.4% (down from 6.4% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Nov 09Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥603, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 30% over the past three years.공고 • Sep 28atect corporation to Report Q2, 2024 Results on Nov 08, 2023atect corporation announced that they will report Q2, 2024 results on Nov 08, 2023Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥739, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 16x in the Life Sciences industry in Japan. Total loss to shareholders of 11% over the past three years.Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: JP¥17.19 (vs JP¥12.22 in 1Q 2023)First quarter 2024 results: EPS: JP¥17.19 (up from JP¥12.22 in 1Q 2023). Revenue: JP¥864.0m (up 15% from 1Q 2023). Net income: JP¥76.0m (up 41% from 1Q 2023). Profit margin: 8.8% (up from 7.2% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Minor Risk Market cap is less than US$100m (JP¥2.91b market cap, or US$20.5m).Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 23%After last week's 23% share price gain to JP¥659, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 21% over the past three years.공고 • Jun 28atect corporation to Report Q1, 2024 Results on Aug 04, 2023atect corporation announced that they will report Q1, 2024 results on Aug 04, 2023Reported Earnings • Jun 28Full year 2023 earnings released: EPS: JP¥35.74 (vs JP¥38.26 in FY 2022)Full year 2023 results: EPS: JP¥35.74 (down from JP¥38.26 in FY 2022). Revenue: JP¥2.96b (down 4.1% from FY 2022). Net income: JP¥158.0m (down 6.5% from FY 2022). Profit margin: 5.3% (down from 5.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 26%After last week's 26% share price gain to JP¥653, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 17x in the Life Sciences industry in Japan. Total loss to shareholders of 25% over the past three years.공고 • May 12atect corporation, Annual General Meeting, Jun 21, 2023atect corporation, Annual General Meeting, Jun 21, 2023.Reported Earnings • May 12Full year 2023 earnings released: EPS: JP¥35.74 (vs JP¥38.26 in FY 2022)Full year 2023 results: EPS: JP¥35.74 (down from JP¥38.26 in FY 2022). Revenue: JP¥2.96b (down 4.1% from FY 2022). Net income: JP¥158.0m (down 6.5% from FY 2022). Profit margin: 5.3% (down from 5.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per share at 1.8% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 23 June 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%).Reported Earnings • Feb 04Third quarter 2023 earnings released: EPS: JP¥7.69 (vs JP¥9.73 in 3Q 2022)Third quarter 2023 results: EPS: JP¥7.69 (down from JP¥9.73 in 3Q 2022). Revenue: JP¥770.0m (up 5.0% from 3Q 2022). Net income: JP¥34.0m (down 21% from 3Q 2022). Profit margin: 4.4% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.공고 • Jan 07atect corporation to Report Q3, 2023 Results on Feb 03, 2023atect corporation announced that they will report Q3, 2023 results on Feb 03, 2023Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Executive Chairman Norio Kotaka was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Nov 06Second quarter 2023 earnings released: EPS: JP¥9.95 (vs JP¥8.37 in 2Q 2022)Second quarter 2023 results: EPS: JP¥9.95 (up from JP¥8.37 in 2Q 2022). Revenue: JP¥690.0m (down 12% from 2Q 2022). Net income: JP¥44.0m (up 19% from 2Q 2022). Profit margin: 6.4% (up from 4.7% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.공고 • Aug 31atect corporation to Report Q2, 2023 Results on Nov 04, 2022atect corporation announced that they will report Q2, 2023 results on Nov 04, 2022Reported Earnings • Aug 07First quarter 2023 earnings released: EPS: JP¥12.22 (vs JP¥16.78 in 1Q 2022)First quarter 2023 results: EPS: JP¥12.22 (down from JP¥16.78 in 1Q 2022). Revenue: JP¥752.0m (down 9.7% from 1Q 2022). Net income: JP¥54.0m (down 27% from 1Q 2022). Profit margin: 7.2% (down from 8.9% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.공고 • Jun 29atect corporation to Report Q1, 2023 Results on Aug 05, 2022atect corporation announced that they will report Q1, 2023 results on Aug 05, 2022Reported Earnings • May 13Full year 2022 earnings released: EPS: JP¥38.26 (vs JP¥17.04 in FY 2021)Full year 2022 results: EPS: JP¥38.26 (up from JP¥17.04 in FY 2021). Revenue: JP¥3.09b (up 8.1% from FY 2021). Net income: JP¥169.0m (up 125% from FY 2021). Profit margin: 5.5% (up from 2.6% in FY 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Executive Chairman Tokuo Kodaka was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Apr 08atect corporation to Report Fiscal Year 2022 Results on May 11, 2022atect corporation announced that they will report fiscal year 2022 results on May 11, 2022Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 23 June 2022. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (2.3%).Valuation Update With 7 Day Price Move • Mar 09Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to JP¥638, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 42% over the past three years.Reported Earnings • Feb 07Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: JP¥9.73 (up from JP¥2.73 in 3Q 2021). Revenue: JP¥733.0m (flat on 3Q 2021). Net income: JP¥43.0m (up 258% from 3Q 2021). Profit margin: 5.9% (up from 1.6% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Reported Earnings • Nov 07Second quarter 2022 earnings released: EPS JP¥8.37 (vs JP¥6.82 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥788.0m (up 14% from 2Q 2021). Net income: JP¥37.0m (up 23% from 2Q 2021). Profit margin: 4.7% (up from 4.4% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 14% per year.Reported Earnings • Aug 12First quarter 2022 earnings released: EPS JP¥16.78 (vs JP¥1.82 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥833.0m (up 26% from 1Q 2021). Net income: JP¥74.0m (up JP¥66.0m from 1Q 2021). Profit margin: 8.9% (up from 1.2% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.Reported Earnings • Jun 27Full year 2021 earnings released: EPS JP¥17.04 (vs JP¥8.67 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥2.86b (down 4.1% from FY 2020). Net income: JP¥75.0m (up 97% from FY 2020). Profit margin: 2.6% (up from 1.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Reported Earnings • May 16Full year 2021 earnings released: EPS JP¥17.04 (vs JP¥8.67 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥2.86b (down 4.1% from FY 2020). Net income: JP¥75.0m (up 97% from FY 2020). Profit margin: 2.6% (up from 1.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.분석 기사 • Apr 22Does atect (TYO:4241) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Upcoming Dividend • Mar 23Upcoming dividend of JP¥5.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 24 June 2021. Trailing yield: 0.3%. Lower than top quartile of Japanese dividend payers (2.7%). Lower than average of industry peers (1.4%).Reported Earnings • Feb 07Third quarter 2021 earnings released: EPS JP¥2.73 (vs JP¥6.16 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: JP¥740.0m (up 1.4% from 3Q 2020). Net income: JP¥12.0m (down 56% from 3Q 2020). Profit margin: 1.6% (down from 3.7% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.분석 기사 • Jan 07Should We Be Cautious About atect corporation's (TYO:4241) ROE Of 0.8%?One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...Is New 90 Day High Low • Dec 23New 90-day low: JP¥852The company is down 5.0% from its price of JP¥893 on 24 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 19% over the same period.Reported Earnings • Nov 09Second quarter 2021 earnings released: EPS JP¥6.82The company reported a soft second quarter result with weaker earnings and revenues, although profit margins were improved. Second quarter 2021 results: Revenue: JP¥689.0m (down 12% from 2Q 2020). Net income: JP¥30.0m (down 3.2% from 2Q 2020). Profit margin: 4.4% (up from 4.0% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 18% per year.매출 및 비용 세부 내역atect가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이TSE:4241 매출, 비용 및 순이익 (JPY Millions)날짜매출순이익일반관리비연구개발비31 Mar 263,3571411,125231 Dec 253,2831321,134430 Sep 253,180981,156430 Jun 253,139581,178431 Mar 253,201401,203431 Dec 243,150-3051,10714030 Sep 243,128-3241,15414030 Jun 243,199-2801,17214031 Mar 243,175-2441,17314031 Dec 233,1991131,12216930 Sep 233,2181641,07616930 Jun 233,0731801,03416931 Mar 232,9611581,02516931 Dec 222,9441471,00119630 Sep 222,90715699519630 Jun 223,0051491,05919631 Mar 223,0861691,05619631 Dec 213,1161791,06818130 Sep 213,1231481,06418130 Jun 213,02414199618131 Mar 212,8557598218131 Dec 202,797-189326630 Sep 202,7871491926630 Jun 202,8821598226631 Mar 202,977381,00726631 Dec 192,996791,05422930 Sep 193,052941,03422930 Jun 193,01512497622931 Mar 192,95512793322931 Dec 182,85114695117830 Sep 182,76013193617830 Jun 182,71310394617831 Mar 182,6698295217831 Dec 172,695501,133030 Sep 172,616631,104030 Jun 172,542721,062031 Mar 172,483511,033031 Dec 162,425311,005030 Sep 162,44547987030 Jun 162,4467981031 Mar 162,47375967031 Dec 152,4551228568330 Sep 152,44311785983양질의 수익: 4241는 고품질 수익을 보유하고 있습니다.이익 마진 증가: 4241의 현재 순 이익률 (4.2%)은 지난해 (1.2%)보다 높습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: 4241의 수익은 지난 5년 동안 연평균 25% 감소했습니다.성장 가속화: 지난 1년간 4241 의 수익 증가율(252.5%)은 연간 평균(-25%)을 초과합니다.수익 대 산업: 4241의 지난 1년 수익 증가율(252.5%)은 Life Sciences 업계의 -16.4%를 상회했습니다.자기자본이익률높은 ROE: 4241의 자본 수익률(7.7%)은 낮음으로 평가됩니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/07/29 16:02종가2026/07/29 00:00수익2026/03/31연간 수익2026/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스atect corporation는 1명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Hitoshi SakamotoMizuho Securities Co., Ltd.
공고 • Jun 28atect corporation to Report Q1, 2027 Results on Aug 07, 2026atect corporation announced that they will report Q1, 2027 results on Aug 07, 2026
Reported Earnings • May 17Full year 2026 earnings released: EPS: JP¥31.89 (vs JP¥9.05 in FY 2025)Full year 2026 results: EPS: JP¥31.89 (up from JP¥9.05 in FY 2025). Revenue: JP¥3.36b (up 4.9% from FY 2025). Net income: JP¥141.0m (up 253% from FY 2025). Profit margin: 4.2% (up from 1.2% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥8.14 (vs JP¥0.45 in 3Q 2025)Third quarter 2026 results: EPS: JP¥8.14 (up from JP¥0.45 in 3Q 2025). Revenue: JP¥876.0m (up 13% from 3Q 2025). Net income: JP¥36.0m (up JP¥34.0m from 3Q 2025). Profit margin: 4.1% (up from 0.3% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
공고 • Dec 03atect corporation to Report Q3, 2026 Results on Feb 13, 2026atect corporation announced that they will report Q3, 2026 results on Feb 13, 2026
공고 • Nov 05atect corporation to Report Q2, 2026 Results on Nov 14, 2025atect corporation announced that they will report Q2, 2026 results on Nov 14, 2025
Reported Earnings • Aug 10First quarter 2026 earnings released: EPS: JP¥13.12 (vs JP¥9.05 in 1Q 2025)First quarter 2026 results: EPS: JP¥13.12 (up from JP¥9.05 in 1Q 2025). Revenue: JP¥826.0m (down 7.0% from 1Q 2025). Net income: JP¥58.0m (up 45% from 1Q 2025). Profit margin: 7.0% (up from 4.5% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
공고 • Jun 28atect corporation to Report Q1, 2027 Results on Aug 07, 2026atect corporation announced that they will report Q1, 2027 results on Aug 07, 2026
Reported Earnings • May 17Full year 2026 earnings released: EPS: JP¥31.89 (vs JP¥9.05 in FY 2025)Full year 2026 results: EPS: JP¥31.89 (up from JP¥9.05 in FY 2025). Revenue: JP¥3.36b (up 4.9% from FY 2025). Net income: JP¥141.0m (up 253% from FY 2025). Profit margin: 4.2% (up from 1.2% in FY 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 3% per year but the company’s share price has increased by 10% per year, which means it is well ahead of earnings.
공고 • May 13atect corporation, Annual General Meeting, Jun 24, 2026atect corporation, Annual General Meeting, Jun 24, 2026.
Valuation Update With 7 Day Price Move • May 13Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥890, the stock trades at a trailing P/E ratio of 29.8x. Average trailing P/E is 23x in the Life Sciences industry in Japan. Total returns to shareholders of 81% over the past three years.
Valuation Update With 7 Day Price Move • Apr 16Investor sentiment improves as stock rises 17%After last week's 17% share price gain to JP¥817, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 22x in the Life Sciences industry in Japan. Total returns to shareholders of 47% over the past three years.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 30 March 2026. Payment date: 26 June 2026. Payout ratio is a comfortable 33% and this is well supported by cash flows. Trailing yield: 1.5%. Lower than top quartile of Japanese dividend payers (3.6%). Lower than average of industry peers (2.8%).
Valuation Update With 7 Day Price Move • Mar 04Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to JP¥741, the stock trades at a trailing P/E ratio of 24.8x. Average trailing P/E is 25x in the Life Sciences industry in Japan. Total returns to shareholders of 38% over the past three years.
Reported Earnings • Feb 16Third quarter 2026 earnings released: EPS: JP¥8.14 (vs JP¥0.45 in 3Q 2025)Third quarter 2026 results: EPS: JP¥8.14 (up from JP¥0.45 in 3Q 2025). Revenue: JP¥876.0m (up 13% from 3Q 2025). Net income: JP¥36.0m (up JP¥34.0m from 3Q 2025). Profit margin: 4.1% (up from 0.3% in 3Q 2025). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has fallen by 28% per year but the company’s share price has increased by 13% per year, which means it is well ahead of earnings.
Valuation Update With 7 Day Price Move • Feb 16Investor sentiment improves as stock rises 20%After last week's 20% share price gain to JP¥749, the stock trades at a trailing P/E ratio of 33.8x. Average trailing P/E is 24x in the Life Sciences industry in Japan. Total returns to shareholders of 52% over the past three years.
New Risk • Jan 28New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.1% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (6.1% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.1% average weekly change). Earnings have declined by 31% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥3.00b market cap, or US$19.7m).
Valuation Update With 7 Day Price Move • Jan 28Investor sentiment improves as stock rises 18%After last week's 18% share price gain to JP¥684, the stock trades at a trailing P/E ratio of 30.9x. Average trailing P/E is 24x in the Life Sciences industry in Japan. Total returns to shareholders of 34% over the past three years.
분석 기사 • Jan 20atect corporation's (TSE:4241) Prospects Need A Boost To Lift SharesWith a price-to-sales (or "P/S") ratio of 0.8x atect corporation ( TSE:4241 ) may be sending bullish signals at the...
공고 • Dec 03atect corporation to Report Q3, 2026 Results on Feb 13, 2026atect corporation announced that they will report Q3, 2026 results on Feb 13, 2026
Valuation Update With 7 Day Price Move • Dec 01Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥510, the stock trades at a trailing P/E ratio of 38.9x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total returns to shareholders of 6.1% over the past three years.
분석 기사 • Nov 27atect (TSE:4241) Seems To Use Debt Quite SensiblyHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Nov 27New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.6% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 33% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.6% average weekly change). Large one-off items impacting financial results. Market cap is less than US$100m (JP¥2.25b market cap, or US$14.4m).
공고 • Nov 05atect corporation to Report Q2, 2026 Results on Nov 14, 2025atect corporation announced that they will report Q2, 2026 results on Nov 14, 2025
Reported Earnings • Aug 10First quarter 2026 earnings released: EPS: JP¥13.12 (vs JP¥9.05 in 1Q 2025)First quarter 2026 results: EPS: JP¥13.12 (up from JP¥9.05 in 1Q 2025). Revenue: JP¥826.0m (down 7.0% from 1Q 2025). Net income: JP¥58.0m (up 45% from 1Q 2025). Profit margin: 7.0% (up from 4.5% in 1Q 2025). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance.
New Risk • Aug 10New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 27% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (5.8% operating cash flow to total debt). Earnings have declined by 33% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Market cap is less than US$100m (JP¥1.86b market cap, or US$12.6m).
공고 • Aug 02atect corporation to Report Q1, 2026 Results on Aug 08, 2025atect corporation announced that they will report Q1, 2026 results on Aug 08, 2025
Reported Earnings • May 21Full year 2025 earnings released: EPS: JP¥9.05 (vs JP¥55.19 loss in FY 2024)Full year 2025 results: EPS: JP¥9.05 (up from JP¥55.19 loss in FY 2024). Revenue: JP¥3.20b (flat on FY 2024). Net income: JP¥40.0m (up JP¥284.0m from FY 2024). Profit margin: 1.2% (up from net loss in FY 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 67 percentage points per year, which is a significant difference in performance.
공고 • May 15atect corporation, Annual General Meeting, Jun 25, 2025atect corporation, Annual General Meeting, Jun 25, 2025.
공고 • Mar 27atect corporation to Report Fiscal Year 2025 Results on May 14, 2025atect corporation announced that they will report fiscal year 2025 results on May 14, 2025
Upcoming Dividend • Mar 21Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 28 March 2025. Payment date: 27 June 2025. The company is not currently making a profit and there are not enough cash flows to support it either. Trailing yield: 2.2%. Lower than top quartile of Japanese dividend payers (3.7%). Lower than average of industry peers (2.8%).
New Risk • Feb 27New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.3% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.1x net interest cover). Share price has been highly volatile over the past 3 months (8.3% average weekly change). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 36% per year over the past 5 years. Minor Risk Market cap is less than US$100m (JP¥2.26b market cap, or US$15.1m).
Reported Earnings • Feb 08Third quarter 2025 earnings released: EPS: JP¥0.45 (vs JP¥3.85 loss in 3Q 2024)Third quarter 2025 results: EPS: JP¥0.45 (up from JP¥3.85 loss in 3Q 2024). Revenue: JP¥773.0m (up 2.9% from 3Q 2024). Net income: JP¥2.00m (up JP¥19.0m from 3Q 2024). Profit margin: 0.3% (up from net loss in 3Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 74 percentage points per year, which is a significant difference in performance.
분석 기사 • Jan 30Revenues Working Against atect corporation's (TSE:4241) Share Priceatect corporation's ( TSE:4241 ) price-to-sales (or "P/S") ratio of 0.6x might make it look like a strong buy right now...
공고 • Jan 17atect corporation to Report Q3, 2025 Results on Feb 07, 2025atect corporation announced that they will report Q3, 2025 results on Feb 07, 2025
New Risk • Jan 09New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Japanese stocks, typically moving 5.2% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.1% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 26% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (5.2% average weekly change). Market cap is less than US$100m (JP¥1.88b market cap, or US$11.9m).
New Risk • Dec 25New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: JP¥1.57b (US$9.99m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (4.1% operating cash flow to total debt). Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Cash payout ratio: 158% Earnings have declined by 26% per year over the past 5 years. Market cap is less than US$10m (JP¥1.57b market cap, or US$9.99m).
Reported Earnings • Nov 11Second quarter 2025 earnings released: JP¥3.62 loss per share (vs JP¥6.33 profit in 2Q 2024)Second quarter 2025 results: JP¥3.62 loss per share (down from JP¥6.33 profit in 2Q 2024). Revenue: JP¥764.0m (down 8.5% from 2Q 2024). Net loss: JP¥16.0m (down 157% from profit in 2Q 2024). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 59 percentage points per year, which is a significant difference in performance.
Buy Or Sell Opportunity • Nov 11Now 24% undervalued after recent price dropOver the last 90 days, the stock has fallen 16% to JP¥464. The fair value is estimated to be JP¥614, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company became loss making.
공고 • Oct 11atect corporation to Report Q2, 2025 Results on Nov 08, 2024atect corporation announced that they will report Q2, 2025 results on Nov 08, 2024
New Risk • Sep 17New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risk No financial data reported. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Market cap is less than US$100m (JP¥2.26b market cap, or US$16.1m).
분석 기사 • Aug 06atect corporation (TSE:4241) Looks Inexpensive After Falling 33% But Perhaps Not Attractive EnoughThe atect corporation ( TSE:4241 ) share price has fared very poorly over the last month, falling by a substantial 33...
분석 기사 • Aug 04atect (TSE:4241) Has A Somewhat Strained Balance SheetDavid Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
공고 • Jul 17atect corporation to Report Q1, 2025 Results on Aug 07, 2024atect corporation announced that they will report Q1, 2025 results on Aug 07, 2024
New Risk • May 17New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Operating cash flow to total debt ratio: 19% This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (19% operating cash flow to total debt). Minor Risks Share price has been volatile over the past 3 months (6.2% average weekly change). Market cap is less than US$100m (JP¥3.19b market cap, or US$20.5m).
Reported Earnings • May 13Full year 2024 earnings released: JP¥55.19 loss per share (vs JP¥35.74 profit in FY 2023)Full year 2024 results: JP¥55.19 loss per share (down from JP¥35.74 profit in FY 2023). Revenue: JP¥3.18b (up 7.2% from FY 2023). Net loss: JP¥244.0m (down 254% from profit in FY 2023). Over the last 3 years on average, earnings per share has fallen by 29% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
공고 • May 12atect corporation, Annual General Meeting, Jun 26, 2024atect corporation, Annual General Meeting, Jun 26, 2024.
Buy Or Sell Opportunity • Apr 12Now 21% undervalued after recent price dropOver the last 90 days, the stock has fallen 32% to JP¥790. The fair value is estimated to be JP¥1,004, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.
공고 • Mar 28atect corporation to Report Fiscal Year 2024 Results on May 10, 2024atect corporation announced that they will report fiscal year 2024 results on May 10, 2024
Buy Or Sell Opportunity • Mar 26Now 21% undervaluedOver the last 90 days, the stock has risen 12% to JP¥789. The fair value is estimated to be JP¥1,005, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.
Upcoming Dividend • Mar 21Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 28 March 2024. Payment date: 24 June 2024. Payout ratio is a comfortable 39% and this is well supported by cash flows. Trailing yield: 1.2%. Lower than top quartile of Japanese dividend payers (3.2%). Lower than average of industry peers (2.3%).
Buy Or Sell Opportunity • Mar 11Now 22% undervaluedOver the last 90 days, the stock has risen 12% to JP¥792. The fair value is estimated to be JP¥1,017, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Meanwhile, the company has become profitable.
Valuation Update With 7 Day Price Move • Feb 14Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥870, the stock trades at a trailing P/E ratio of 34x. Average trailing P/E is 14x in the Life Sciences industry in Japan. Total loss to shareholders of 3.8% over the past three years.
Reported Earnings • Feb 09Third quarter 2024 earnings released: JP¥3.85 loss per share (vs JP¥7.69 profit in 3Q 2023)Third quarter 2024 results: JP¥3.85 loss per share (down from JP¥7.69 profit in 3Q 2023). Revenue: JP¥751.0m (down 2.5% from 3Q 2023). Net loss: JP¥17.0m (down 150% from profit in 3Q 2023). Over the last 3 years on average, earnings per share has increased by 20% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jan 26Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to JP¥1,080, the stock trades at a trailing P/E ratio of 29.1x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total returns to shareholders of 15% over the past three years.
공고 • Jan 11atect corporation to Report Q3, 2024 Results on Feb 07, 2024atect corporation announced that they will report Q3, 2024 results on Feb 07, 2024
Valuation Update With 7 Day Price Move • Dec 28Investor sentiment improves as stock rises 15%After last week's 15% share price gain to JP¥782, the stock trades at a trailing P/E ratio of 21.1x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 7.8% over the past three years.
Valuation Update With 7 Day Price Move • Nov 30Investor sentiment improves as stock rises 22%After last week's 22% share price gain to JP¥801, the stock trades at a trailing P/E ratio of 21.6x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 20% over the past three years.
Reported Earnings • Nov 11Second quarter 2024 earnings released: EPS: JP¥6.33 (vs JP¥9.95 in 2Q 2023)Second quarter 2024 results: EPS: JP¥6.33 (down from JP¥9.95 in 2Q 2023). Revenue: JP¥835.0m (up 21% from 2Q 2023). Net income: JP¥28.0m (down 36% from 2Q 2023). Profit margin: 3.4% (down from 6.4% in 2Q 2023). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Nov 09Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to JP¥603, the stock trades at a trailing P/E ratio of 14.8x. Average trailing P/E is 15x in the Life Sciences industry in Japan. Total loss to shareholders of 30% over the past three years.
공고 • Sep 28atect corporation to Report Q2, 2024 Results on Nov 08, 2023atect corporation announced that they will report Q2, 2024 results on Nov 08, 2023
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 16%After last week's 16% share price gain to JP¥739, the stock trades at a trailing P/E ratio of 18.2x. Average trailing P/E is 16x in the Life Sciences industry in Japan. Total loss to shareholders of 11% over the past three years.
Reported Earnings • Aug 09First quarter 2024 earnings released: EPS: JP¥17.19 (vs JP¥12.22 in 1Q 2023)First quarter 2024 results: EPS: JP¥17.19 (up from JP¥12.22 in 1Q 2023). Revenue: JP¥864.0m (up 15% from 1Q 2023). Net income: JP¥76.0m (up 41% from 1Q 2023). Profit margin: 8.8% (up from 7.2% in 1Q 2023). The increase in margin was driven by higher revenue. Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 6% per year, which means it is significantly lagging earnings.
New Risk • Aug 08New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Japanese stocks, typically moving 8.5% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (13% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (8.5% average weekly change). Minor Risk Market cap is less than US$100m (JP¥2.91b market cap, or US$20.5m).
Valuation Update With 7 Day Price Move • Aug 07Investor sentiment improves as stock rises 23%After last week's 23% share price gain to JP¥659, the stock trades at a trailing P/E ratio of 18.4x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 21% over the past three years.
공고 • Jun 28atect corporation to Report Q1, 2024 Results on Aug 04, 2023atect corporation announced that they will report Q1, 2024 results on Aug 04, 2023
Reported Earnings • Jun 28Full year 2023 earnings released: EPS: JP¥35.74 (vs JP¥38.26 in FY 2022)Full year 2023 results: EPS: JP¥35.74 (down from JP¥38.26 in FY 2022). Revenue: JP¥2.96b (down 4.1% from FY 2022). Net income: JP¥158.0m (down 6.5% from FY 2022). Profit margin: 5.3% (down from 5.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 11% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Jun 01Investor sentiment improves as stock rises 26%After last week's 26% share price gain to JP¥653, the stock trades at a trailing P/E ratio of 18.3x. Average trailing P/E is 17x in the Life Sciences industry in Japan. Total loss to shareholders of 25% over the past three years.
공고 • May 12atect corporation, Annual General Meeting, Jun 21, 2023atect corporation, Annual General Meeting, Jun 21, 2023.
Reported Earnings • May 12Full year 2023 earnings released: EPS: JP¥35.74 (vs JP¥38.26 in FY 2022)Full year 2023 results: EPS: JP¥35.74 (down from JP¥38.26 in FY 2022). Revenue: JP¥2.96b (down 4.1% from FY 2022). Net income: JP¥158.0m (down 6.5% from FY 2022). Profit margin: 5.3% (down from 5.5% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per share at 1.8% yieldEligible shareholders must have bought the stock before 30 March 2023. Payment date: 23 June 2023. Payout ratio is a comfortable 30% and this is well supported by cash flows. Trailing yield: 1.8%. Lower than top quartile of Japanese dividend payers (3.6%). Higher than average of industry peers (1.6%).
Reported Earnings • Feb 04Third quarter 2023 earnings released: EPS: JP¥7.69 (vs JP¥9.73 in 3Q 2022)Third quarter 2023 results: EPS: JP¥7.69 (down from JP¥9.73 in 3Q 2022). Revenue: JP¥770.0m (up 5.0% from 3Q 2022). Net income: JP¥34.0m (down 21% from 3Q 2022). Profit margin: 4.4% (down from 5.9% in 3Q 2022). The decrease in margin was driven by higher expenses. Over the last 3 years on average, earnings per share has increased by 53% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
공고 • Jan 07atect corporation to Report Q3, 2023 Results on Feb 03, 2023atect corporation announced that they will report Q3, 2023 results on Feb 03, 2023
Board Change • Nov 16Less than half of directors are independentFollowing the recent departure of a director, there is only 1 independent director on the board. The company's board is composed of: 1 independent director. 2 non-independent directors. Executive Chairman Norio Kotaka was the last director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Nov 06Second quarter 2023 earnings released: EPS: JP¥9.95 (vs JP¥8.37 in 2Q 2022)Second quarter 2023 results: EPS: JP¥9.95 (up from JP¥8.37 in 2Q 2022). Revenue: JP¥690.0m (down 12% from 2Q 2022). Net income: JP¥44.0m (up 19% from 2Q 2022). Profit margin: 6.4% (up from 4.7% in 2Q 2022). Over the last 3 years on average, earnings per share has increased by 48% per year but the company’s share price has fallen by 27% per year, which means it is significantly lagging earnings.
공고 • Aug 31atect corporation to Report Q2, 2023 Results on Nov 04, 2022atect corporation announced that they will report Q2, 2023 results on Nov 04, 2022
Reported Earnings • Aug 07First quarter 2023 earnings released: EPS: JP¥12.22 (vs JP¥16.78 in 1Q 2022)First quarter 2023 results: EPS: JP¥12.22 (down from JP¥16.78 in 1Q 2022). Revenue: JP¥752.0m (down 9.7% from 1Q 2022). Net income: JP¥54.0m (down 27% from 1Q 2022). Profit margin: 7.2% (down from 8.9% in 1Q 2022). Over the last 3 years on average, earnings per share has increased by 36% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
공고 • Jun 29atect corporation to Report Q1, 2023 Results on Aug 05, 2022atect corporation announced that they will report Q1, 2023 results on Aug 05, 2022
Reported Earnings • May 13Full year 2022 earnings released: EPS: JP¥38.26 (vs JP¥17.04 in FY 2021)Full year 2022 results: EPS: JP¥38.26 (up from JP¥17.04 in FY 2021). Revenue: JP¥3.09b (up 8.1% from FY 2021). Net income: JP¥169.0m (up 125% from FY 2021). Profit margin: 5.5% (up from 2.6% in FY 2021). Over the last 3 years on average, earnings per share has increased by 23% per year but the company’s share price has fallen by 14% per year, which means it is significantly lagging earnings.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 3 non-independent directors. Executive Chairman Tokuo Kodaka was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Apr 08atect corporation to Report Fiscal Year 2022 Results on May 11, 2022atect corporation announced that they will report fiscal year 2022 results on May 11, 2022
Upcoming Dividend • Mar 23Upcoming dividend of JP¥10.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 23 June 2022. Payout ratio is a comfortable 12% and this is well supported by cash flows. Trailing yield: 1.3%. Lower than top quartile of Japanese dividend payers (3.4%). Lower than average of industry peers (2.3%).
Valuation Update With 7 Day Price Move • Mar 09Investor sentiment deteriorated over the past weekAfter last week's 17% share price decline to JP¥638, the stock trades at a trailing P/E ratio of 15.8x. Average trailing P/E is 18x in the Life Sciences industry in Japan. Total loss to shareholders of 42% over the past three years.
Reported Earnings • Feb 07Third quarter 2022 earnings: Revenues and EPS in line with analyst expectationsThird quarter 2022 results: EPS: JP¥9.73 (up from JP¥2.73 in 3Q 2021). Revenue: JP¥733.0m (flat on 3Q 2021). Net income: JP¥43.0m (up 258% from 3Q 2021). Profit margin: 5.9% (up from 1.6% in 3Q 2021). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 2% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Reported Earnings • Nov 07Second quarter 2022 earnings released: EPS JP¥8.37 (vs JP¥6.82 in 2Q 2021)The company reported a strong second quarter result with improved earnings, revenues and profit margins. Second quarter 2022 results: Revenue: JP¥788.0m (up 14% from 2Q 2021). Net income: JP¥37.0m (up 23% from 2Q 2021). Profit margin: 4.7% (up from 4.4% in 2Q 2021). Over the last 3 years on average, earnings per share has fallen by 19% per year whereas the company’s share price has fallen by 14% per year.
Reported Earnings • Aug 12First quarter 2022 earnings released: EPS JP¥16.78 (vs JP¥1.82 in 1Q 2021)The company reported a strong first quarter result with improved earnings, revenues and profit margins. First quarter 2022 results: Revenue: JP¥833.0m (up 26% from 1Q 2021). Net income: JP¥74.0m (up JP¥66.0m from 1Q 2021). Profit margin: 8.9% (up from 1.2% in 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 34% per year but the company’s share price has only fallen by 7% per year, which means it has not declined as severely as earnings.
Reported Earnings • Jun 27Full year 2021 earnings released: EPS JP¥17.04 (vs JP¥8.67 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥2.86b (down 4.1% from FY 2020). Net income: JP¥75.0m (up 97% from FY 2020). Profit margin: 2.6% (up from 1.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Reported Earnings • May 16Full year 2021 earnings released: EPS JP¥17.04 (vs JP¥8.67 in FY 2020)The company reported a decent full year result with improved earnings and profit margins, although revenues were weaker. Full year 2021 results: Revenue: JP¥2.86b (down 4.1% from FY 2020). Net income: JP¥75.0m (up 97% from FY 2020). Profit margin: 2.6% (up from 1.3% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
분석 기사 • Apr 22Does atect (TYO:4241) Have A Healthy Balance Sheet?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Upcoming Dividend • Mar 23Upcoming dividend of JP¥5.00 per shareEligible shareholders must have bought the stock before 30 March 2021. Payment date: 24 June 2021. Trailing yield: 0.3%. Lower than top quartile of Japanese dividend payers (2.7%). Lower than average of industry peers (1.4%).
Reported Earnings • Feb 07Third quarter 2021 earnings released: EPS JP¥2.73 (vs JP¥6.16 in 3Q 2020)The company reported a soft third quarter result with weaker earnings and profit margins, although revenues improved. Third quarter 2021 results: Revenue: JP¥740.0m (up 1.4% from 3Q 2020). Net income: JP¥12.0m (down 56% from 3Q 2020). Profit margin: 1.6% (down from 3.7% in 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 42% per year but the company’s share price has only fallen by 12% per year, which means it has not declined as severely as earnings.
분석 기사 • Jan 07Should We Be Cautious About atect corporation's (TYO:4241) ROE Of 0.8%?One of the best investments we can make is in our own knowledge and skill set. With that in mind, this article will...
Is New 90 Day High Low • Dec 23New 90-day low: JP¥852The company is down 5.0% from its price of JP¥893 on 24 September 2020. The Japanese market is up 7.0% over the last 90 days, indicating the company underperformed over that time. However, it outperformed the Life Sciences industry, which is down 19% over the same period.
Reported Earnings • Nov 09Second quarter 2021 earnings released: EPS JP¥6.82The company reported a soft second quarter result with weaker earnings and revenues, although profit margins were improved. Second quarter 2021 results: Revenue: JP¥689.0m (down 12% from 2Q 2020). Net income: JP¥30.0m (down 3.2% from 2Q 2020). Profit margin: 4.4% (up from 4.0% in 2Q 2020). The increase in margin was driven by lower expenses. Over the last 3 years on average, earnings per share has fallen by 22% per year whereas the company’s share price has fallen by 18% per year.